

16_rFXIII Trade name
From: ROFI (Robert Fischer) <rofi@novonordisk.com>
Sent: Friday, May 10, 2013 10:12 AM
To: Qian, Jiahua
Subject: rFXIII Trade name
Attachments: emfinfo.txt; emfinfo.txt

Dear Jiahua,

Per our telephone conversation, Novo Nordisk accepts the Division's comment regarding the proposed trade name for rFXIII and will agree to the trade name of "Novothirteen" for the product.

We can submit an amendment to the BLA confirming our trade name proposal if required.

Thank you, Bob

Robert Fischer
Sr. Director, Regulatory Affairs
CMR

Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, New Jersey 08536
USA
+1-609-987-5891 (direct)
(b) (6)
rofi@novonordisk.com

This e-mail (including any attachments) is intended for the addressee(s) stated above only and may contain confidential information protected by law. You are hereby notified that any unauthorized reading, disclosure, copying or distribution of this e-mail or use of information contained herein is strictly prohibited and may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete it immediately hereafter. Thank you.